Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsScientists discuss molecular maintenance in leukemia stem cells in chronic myeloid leukemia and provide a more in-depth discussion of the dual-specificity kinase DYRK2, which has been identified as a novel actionable checkpoint in a critical leukemic network.
[Experimental and Molecular Medicine]
6445212 {6445212:V33THR3C} apa 50 1 155265 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-6ab96e610b14835fc9fc0d9f661d2238%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22V33THR3C%22%2C%22library%22%3A%7B%22id%22%3A6445212%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Park%20and%20Lacorazza%22%2C%22parsedDate%22%3A%222020-10-16%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPark%2C%20C.%20S.%2C%20%26amp%3B%20Lacorazza%2C%20H.%20D.%20%282020%29.%20DYRK2%20controls%20a%20key%20regulatory%20network%20in%20chronic%20myeloid%20leukemia%20stem%20cells.%20%3Ci%3EExperimental%20%26amp%3B%20Molecular%20Medicine%3C%5C%2Fi%3E%2C%201%26%23x2013%3B10.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs12276-020-00515-5%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs12276-020-00515-5%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445212%26amp%3Bitem_key%3DV33THR3C%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22DYRK2%20controls%20a%20key%20regulatory%20network%20in%20chronic%20myeloid%20leukemia%20stem%20cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chun%20Shik%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20Daniel%22%2C%22lastName%22%3A%22Lacorazza%22%7D%5D%2C%22abstractNote%22%3A%22Chronic%20myeloid%20leukemia%20is%20a%20hematological%20cancer%20driven%20by%20the%20oncoprotein%20BCR-ABL1%2C%20and%20lifelong%20treatment%20with%20tyrosine%20kinase%20inhibitors%20extends%20patient%20survival%20to%20nearly%20the%20life%20expectancy%20of%20the%20general%20population.%20Despite%20advances%20in%20the%20development%20of%20more%20potent%20tyrosine%20kinase%20inhibitors%20to%20induce%20a%20durable%20deep%20molecular%20response%2C%20more%20than%20half%20of%20patients%20relapse%20upon%20treatment%20discontinuation.%20This%20clinical%20finding%20supports%20the%20paradigm%20that%20leukemia%20stem%20cells%20feed%20the%20neoplasm%2C%20resist%20tyrosine%20kinase%20inhibition%2C%20and%20reactivate%20upon%20drug%20withdrawal%20depending%20on%20the%20fitness%20of%20the%20patient%5Cu2019s%20immune%20surveillance.%20This%20concept%20lends%20support%20to%20the%20idea%20that%20treatment-free%20remission%20is%20not%20achieved%20solely%20with%20tyrosine%20kinase%20inhibitors%20and%20that%20new%20molecular%20targets%20independent%20of%20BCR-ABL1%20signaling%20are%20needed%20in%20order%20to%20develop%20adjuvant%20therapy%20to%20more%20efficiently%20eradicate%20the%20leukemia%20stem%20cell%20population%20responsible%20for%20chemoresistance%20and%20relapse.%20Future%20efforts%20must%20focus%20on%20the%20identification%20of%20new%20targets%20to%20support%20the%20discovery%20of%20potent%20and%20safe%20small%20molecules%20able%20to%20specifically%20eradicate%20the%20leukemic%20stem%20cell%20population.%20In%20this%20review%2C%20we%20briefly%20discuss%20molecular%20maintenance%20in%20leukemia%20stem%20cells%20in%20chronic%20myeloid%20leukemia%20and%20provide%20a%20more%20in-depth%20discussion%20of%20the%20dual-specificity%20kinase%20DYRK2%2C%20which%20has%20been%20identified%20as%20a%20novel%20actionable%20checkpoint%20in%20a%20critical%20leukemic%20network.%20DYRK2%20controls%20the%20activation%20of%20p53%20and%20proteasomal%20degradation%20of%20c-MYC%2C%20leading%20to%20impaired%20survival%20and%20self-renewal%20of%20leukemia%20stem%20cells%3B%20thus%2C%20pharmacological%20activation%20of%20DYRK2%20as%20an%20adjuvant%20to%20standard%20therapy%20has%20the%20potential%20to%20induce%20treatment-free%20remission.%22%2C%22date%22%3A%222020-10-16%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs12276-020-00515-5%22%2C%22ISSN%22%3A%222092-6413%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs12276-020-00515-5%22%2C%22deleted%22%3A1%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222020-10-16T16%3A15%3A41Z%22%7D%7D%5D%7D
Park, C. S., & Lacorazza, H. D. (2020). DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells. Experimental & Molecular Medicine, 1–10. https://doi.org/10.1038/s12276-020-00515-5 Cite
